Howard Larkin
Published: Thursday, April 2, 2020
A fully automated robotic cataract surgery platform that extracts the nucleus and cortical materials has been successfully tested in pig eyes and could enter human trials in three-to-four years, Jean-Pierre Hubschman MD told a session of the American Academy of Ophthalmology Annual Meeting in San Francisco.
Known as IRISS, the automated cataract platform uses a complete preoperative OCT scan to construct a 3D model of the eye and plan surgery. Planning includes determining the precise trajectory of instrument tips to be used throughout the procedure, explained Dr Hubschman, of the University of California-Los Angeles, USA.
Precise guidance
During surgery, real-time OCT data acquisition and processing provide precise guidance to the instrument inside the eye, allowing automated cleaning of the lens and cortical material located in capsular bag. A surgeon monitors the operation and can override the device if necessary, said Dr Hubschman, of the Stein Eye Institute and Director of the Advanced Robotic Eye Surgery
Lab at UCLA.
In a study involving fully automated surgery on 30 harvested pig eyes, all lens material was successfully removed from 25 eyes, with minute particles left behind or attached to the iris or capsule in five eyes, Dr Hubschman reported. No posterior capsule ruptures occurred and completion time averaged less than five minutes.
Potential advantages of automated surgery include more complete nucleus and cortex removal and reduced risk of capsule rupture, Dr Hubschman said. This is done by providing better visualisation of the anatomical structures during the procedure, for example providing complete visualisation of the capsule periphery, which is normally hidden by the iris in manual surgery. He hopes to automate capsule polishing and IOL alignment soon.
“It takes the guesswork out of surgery,” he noted.
Limits hand tremor
Semi-automated systems envisioned for vitreoretinal surgery eliminate physiological tremor in surgeons’ hands and provides augmented visual and tactile feedback, enhancing precision and control, Dr Hubschman added. These include a semi-automated robot-assisted retinal vein cannulation device that limits hand tremor and maintains a stable position with a surgeon operating the device, Dr Hubschman said.
A robotic device known as Preceyes for retinal membrane peeling and subretinal injections operated by a surgeon from a console also has been tested in humans.
Dr Hubschman and colleagues are developing the IRISS platform for fully automated cataract surgery and semi-automated retinal surgery, enhancing visualisation and increasing feedback. He expects a prototype ready for human trials around 2024.
Jean-Pierre Hubschman: hubschman@jsei.ucla.edu
Tags: ophtalmology robotic surgery
Latest Articles
Simulators Benefit Surgeons and Patients
Helping young surgeons build confidence and expertise.
Read more...
Diamonds in the Rough
The push for inclusivity in ophthalmology.
Read more...
Making Female Leadership More than a Moment
A remarkable global confluence of women in key positions.
Read more...
ESCRS Talks Technology at AAO
Europe adopts technological advances, US still waiting for lenses and lasers.
Read more...
Sorting Out Simultaneous Vision IOLs
The ESCRS Eye Journal Club discuss a new landmark paper on IOL classification and the need for harmonisation of terminology for presbyopic IOLs.
Read more...
Big Advantages to Small-Aperture IOLs
Small-aperture IOLs offer superior image quality with increased range of focus.
Read more...
Prioritising Self-Care
Benefits of maintaining physical, emotional, and mental health extend beyond the personal sphere.
Read more...
Valuing Clinical Trial Design
How inclusivity and diversity can enhance scientific accuracy in research.
Read more...
Knowing Iris Repair: Using Iridodiathermy in Iris Surgery
Prepare for decentred pupils and uneven irides in multiple situations.
Read more...
Neuroprotectant Treatment for MacTel Type 2
Intravitreal implant releasing ciliary neurotrophic factor found safe and effective in pivotal trials.
Read more...